Sector Expert: Ed Arce

H.C. Wainwright & Co.

Image: Ed Arce

Ed Arce is a managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright & Co. Previously, Arce was a senior research analyst with ROTH Capital Partners. Prior to ROTH, he covered biotechnology, biopharmaceutical, specialty pharmaceutical and select medical device companies as an analyst at MLV & Co. Prior to MLV, Arce covered the biotechnology sector at Wedbush Securities, and large-cap pharmaceuticals at UBS Securities. Arce started his equity research career in 2005 as a research associate at First Albany Capital, covering specialty and generic pharmaceutical companies. He holds a master of science degree in finance (MSF) degree from Boston College, as well as a master's degree in business administration and a bachelor's degree in civil engineering, both from Florida International University. Mr. Arce is a board-licensed professional engineer, and a Level III CFA candidate.

Subscribe to
Streetwise Reports

Companies Commented On

  • Allergan Inc.
  • Bristol-Myers Squibb Co.
  • Conatus Pharmaceuticals Inc.
  • CymaBay Therapeutics Inc.
  • DURECT Corp.
  • Galectin Therapeutics Inc.
  • Gilead Sciences Inc.
  • Intercept Pharmaceuticals Inc.
  • Novartis AG
  • Tobira Therapeutics Inc.


Recent Interviews

Small-Caps Rushing to Fill the NASH Treatment Pipeline (5/24/17)
liver630

NASH is an epidemic in the U.S., with more than 100 million people believed to be affected. Yet no FDA-approved treatments are available, with the exception of liver transplantation for end-stage disease. In part two of his interview with The Life Sciences Report, Ed Arce, managing director in equity research and senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, and organizer of the recent inaugural NASH Investor Conference, says that small companies are rushing to fill the pipeline, with numerous compounds in trials.

Big Pharma Sets Its Sights on NASH Epidemic (5/17/17)
Periportal steatosis of the liver

Up to one-third of Americans may have conditions that lead to NASH, yet the disease is far from a household name. Closely linked with obesity, the disease does not become symptomatic until very late stage. Ed Arce, managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright, organized the recent inaugural NASH Investor Conference. In part one of his interview with The Life Sciences Report, Arce discusses the disease, its market potential and how companies large and small are trying to fix the current dearth of treatments.

Minimizing Mistakes in a Volatile Biotech Market: H.C. Wainwright's Ed Arce (2/24/16)
beakermoney630

Continuing stock market volatility is causing some investors to rethink their biotech investments. For generalists, in particular, choosing a winning company is almost a roll of the dice. In this interview with The Life Sciences Report, Ed Arce, a managing director with H.C. Wainwright & Co., shares insights investors can use to avoid mistakes when evaluating up-and-coming companies, and identifies some likely winners for 2016.

Recent Quotes

"DRRX confirmed that it expects to complete patient follow-up visits this quarter, and announce top-line results from the Phase 3 PERSIST study in 4Q17."

— Ed Arce, H.C. Wainwright & Co. (8/14/17)
more >

"Early completion of enrollment for PERSIST, at 12% higher enrollment than targeted, has positive implications for DRRX's Posimir."

— Ed Arce, H.C. Wainwright & Co. (6/28/17)
more >

"DRRX has done a very thorough preclinical program with its compound."

— Ed Arce, H.C. Wainwright & Co. (5/24/17)
more >

"DRRX's deal with a large Pharma partner eliminates investor uncertainty."

— Ed Arce, H.C. Wainwright & Co. (5/12/17)
more >

"DRRX provided a 4Q16 earnings update and indicated that they are actively working towards commencing a Phase 2 trial with an oral formulation of DUR-928 for PSC."

— Ed Arce, H.C. Wainwright & Co. (3/15/17)
more >

"Anticipate the initiation of a Phase 2b trial in acute kidney injury, and especially a potentially positive Phase 2a readout in an undisclosed chronic cholestatic liver disease, both expected later this year, to attract investor attention and interest in the program and DRRX."

— Ed Arce, H.C. Wainwright & Co. (2/28/17)
more >

"Cost analysis on ACRX's Zalviso bolsters a price well above consensus."

— Ed Arce, ROTH Capital Partners (6/3/14)
more >



Due to permission requirements, not all quotes are shown.